Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IZD174 in Parkinson's Disease
NCT04338997Phase 1Withdrawn
- Sponsor
- Inflazome
- Start
- Oct 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of inzomelid in Parkinson's disease (PD), sponsored by Inflazome. Primary endpoints: Concentration of IZD174 in plasma, Concentration of IZD174 in cerebrospinal fluid and 1 more. Planned start Oct 2020; status: withdrawn.
02
Drugs
inzomelid
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04338997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04338997.